Paradigm Biopharmaceuticals (ASX:PAR) Beginning Cash Position: A$16.82 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:PAR Paradigm Biopharmaceuticals Ltd ASX:PAR
21 GF Score
Price A$0.16
! 5 Warning Signs
View Full Analysis

What is Paradigm Biopharmaceuticals Beginning Cash Position?

Paradigm Biopharmaceuticals ASX:PAR 21 Beginning Cash Position is A$16.82 Mil as of Dec. 2025. GuruFocus rates ASX:PAR with a GF Score™ of 21/100. The stock has 5 warning signs investors should review.

Paradigm Biopharmaceuticals's Beginning Cash Position for the quarter that ended in Dec. 2025 was A$16.82 Mil.

Paradigm Biopharmaceuticals's quarterly Beginning Cash Position increased from Dec. 2024 (A$17.82 Mil) to Jun. 2025 (A$24.78 Mil) but then declined from Jun. 2025 (A$24.78 Mil) to Dec. 2025 (A$16.82 Mil).

Paradigm Biopharmaceuticals's annual Beginning Cash Position increased from Jun. 2023 (A$39.67 Mil) to Jun. 2024 (A$56.33 Mil) but then declined from Jun. 2024 (A$56.33 Mil) to Jun. 2025 (A$17.82 Mil).

Paradigm Biopharmaceuticals Beginning Cash Position Related Terms

Paradigm Biopharmaceuticals Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Paradigm Biopharmaceuticals's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paradigm Biopharmaceuticals Beginning Cash Position Chart

Paradigm Biopharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 103.92 71.03 39.67 56.33 17.82

Paradigm Biopharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 56.33 33.51 17.82 24.78 16.82
ASX:PAR
21GF Score
Paradigm Biopharmaceuticals Ltd ASX:PAR
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Paradigm Biopharmaceuticals Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of A$16.82 Mil mean?
Paradigm Biopharmaceuticals (ASX:PAR) has a Beginning Cash Position of A$16.82 Mil as of Dec. 2025. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Paradigm Biopharmaceuticals and its competitors.
Is Paradigm Biopharmaceuticals' Beginning Cash Position too high?
Paradigm Biopharmaceuticals' current Beginning Cash Position is A$16.82 Mil. Overall, Paradigm Biopharmaceuticals has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Paradigm Biopharmaceuticals' Beginning Cash Position compare to VRTX and REGN?
Paradigm Biopharmaceuticals' Beginning Cash Position of A$16.82 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Paradigm Biopharmaceuticals and its competitors. Paradigm Biopharmaceuticals's current Beginning Cash Position is A$16.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paradigm Biopharmaceuticals stock overvalued right now?
Paradigm Biopharmaceuticals (ASX:PAR) has a current Beginning Cash Position of A$16.82 Mil. The current Beginning Cash Position is A$16.82 Mil. Paradigm Biopharmaceuticals' overall GF Score™ is 21/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Paradigm Biopharmaceuticals (ASX:PAR), the current Beginning Cash Position is A$16.82 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Paradigm Biopharmaceuticals Business Description

Other Exchanges PBIGF:USAP86:Germany
Address 500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
21GF Score

Get the complete analysis for ASX:PAR

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.16
Price